CJC-1295 (No DAC) + Ipamorelin

Technical data

INN name

CJC-1295 (No DAC) + Ipamorelin

Identity and composition

The blend of CJC-1295 (No DAC) + Ipamorelin is a lyophilized vial for research (RUO) that combines CJC-1295 without DAC and Ipamorelin in equal parts in a single sterile presentation, available in two presentations: 10 mg total (5 mg of each peptide) and 20 mg total (10 mg of each). CJC-1295 without DAC, also known as Modified GRF 1-29, is a synthetic analog of the first 29 amino acids of growth hormone-releasing hormone (GHRH) with four strategic substitutions (D-Ala2, Gln8, Ala15, Leu27) that confer resistance against the enzyme DPP-IV. Ipamorelin is a growth hormone-releasing pentapeptide secretagogue (GHRP) that acts as a highly selective agonist of the ghrelin receptor (GHSR-1a). By bringing together a GHRH analog and a ghrelin mimetic in a single vial, this blend represents an experimental tool designed to study the synergistic and pulsatile release of GH in laboratory models. Those seeking to buy CJC-1295 Ipamorelin Mexico find in this combination a consolidated object of study of the somatotropic axis. The material is distributed strictly for research (RUO) and meets purity standards documented by lot, being a frequent reference when the CJC-1295 Ipamorelin price is consulted within the catalog of research peptides in Mexico.

Mechanism of action

The mechanism of this GH blend rests on two complementary receptor pathways that converge on the somatotropes of the anterior pituitary. On one hand, CJC-1295 without DAC binds to the GHRH receptor (GHRHR), a Gs-protein-coupled protein that, upon activation, increases adenylate cyclase, raises intracellular cyclic AMP and promotes the synthesis and release of growth hormone, in addition to stimulating transcription of the GH gene. On the other hand, Ipamorelin binds to the ghrelin receptor GHSR-1a, coupled to a Gq protein, which activates phospholipase C, mobilizes intracellular calcium via IP3 and enhances the exocytosis of GH granules. Coactivation of both routes produces a synergistic effect: the GHRH analog amplifies the pulse amplitude while the ghrelin secretagogue partially suppresses somatostatin and adds an independent stimulus, so that the combined GH release observed in models exceeds the sum of each component separately. This dual architecture (GHRHR plus GHSR-1a) reproduces endogenous pulsatile secretion more physiologically and constitutes the scientific rationale for studying the combination rather than a single peptide in research protocols.

Pharmacokinetics

The pharmacokinetics of this blend combine two distinct temporal profiles that complement each other in the study of GH release kinetics. CJC-1295 without DAC, thanks to the D-Ala2, Gln8, Ala15, and Leu27 substitutions, resists degradation by dipeptidyl peptidase IV (DPP-IV) and reaches a half-life of approximately 30 minutes, considerably longer than native GHRH (close to a few minutes) but much shorter than the DAC variant. This brief kinetics generates a sharp, well-defined GH pulse, without prolonged accumulation of the peptide in the circulating compartment. Ipamorelin also has a short half-life, on the order of about two hours in published models, with predominantly renal elimination. The overlap of these two relatively fast-acting peptides favors a coordinated peak of GH secretion followed by a return to baseline, a pattern that is ideal for studying pulsatile dynamics without sustaining continuous supraphysiological levels. In research, this temporal window makes it possible to model how administration frequency influences the response of the GH-IGF-1 axis, a key parameter when characterizing the experimental behavior of the CJC-1295 Ipamorelin combination.

Scientific evidence

The available evidence on this combination comes from independent pharmacological studies of each component and from preclinical work on GH secretagogues. The literature on GHRH analogs has documented that Modified GRF 1-29-type substitutions increase stability against DPP-IV and preserve the capacity to stimulate the release of growth hormone through the GHRHR. For its part, studies on Ipamorelin have characterized its selectivity for the ghrelin receptor and its capacity to induce GH secretion without significantly activating the cortisol and prolactin axes, a finding that differentiates it from earlier secretagogues. The rationale for combining a GHRH analog with a GHRP is supported by classical observations of synergy between the two classes: co-administration amplifies the GH response beyond what would be expected by simple addition. It is important to note that this specific combination is investigated in laboratory models and does not have clinical approvals; all the information is framed within research use (RUO). The body of evidence supports the experimental interest in the synergy, the selectivity of Ipamorelin, and the controlled kinetics of the blend, without extrapolating conclusions to non-experimental contexts.

Research applications

In the research field (RUO), this blend is used as a tool to study the somatotropic axis and the mechanisms that regulate the pulsatile release of growth hormone. Among the frequent lines of study are the characterization of the synergy between GHRH analogs and ghrelin secretagogues, the modeling of the dynamics of the GH-IGF-1 axis, and the comparison of secretion patterns induced by dual stimuli versus single stimuli. Researchers use the combination to explore how the coactivation of GHRHR and GHSR-1a modulates the amplitude and frequency of GH pulses in cell cultures and animal models. It also serves as an experimental reference in structure-activity studies, where the response of the blend is contrasted with that of exogenous somatropin or with that of individual secretagogues. In laboratories that investigate G-protein signaling, this material makes it possible to dissect the relative contributions of the Gs and Gq pathways to GH exocytosis. All of these applications are strictly circumscribed to research contexts, and the CJC-1295 Ipamorelin combination is positioned as a reference GH blend for those who design experimental protocols on the neuroendocrinology of growth in Mexico.

Research protocols

Experimental protocols with this blend describe handling parameters that researchers document by lot to ensure reproducibility. In general terms, laboratory designs contemplate the reconstitution of the lyophilized vial with bacteriostatic water and the preparation of aliquots to minimize freeze-thaw cycles. The short kinetics of both components lead many experimental schemes to evaluate fractionated administrations in order to observe multiple GH pulses over a study window, given that both CJC-1295 without DAC and Ipamorelin return to baseline within a matter of tens of minutes to a few hours. Protocols usually record the final peptide concentration, the reconstitution volume used, and the storage conditions between measurements. The synchrony of the two peptides, both relatively fast-acting, makes it possible to design experiments that capture the coordinated peak of secretion and its decay. It is essential to emphasize that these parameters correspond to research models (RUO) and do not constitute recommendations for use in humans; any dose, frequency, or route described in the literature belongs to the controlled experimental sphere and must be interpreted solely within a rigorous and traceable scientific framework.

Reconstitution

Reconstitution of this lyophilized blend is carried out with bacteriostatic water, typically using between 2 and 3 mL to dissolve the contents of the 5 mg + 5 mg vial. The procedure recommended in peptide handling consists of tilting the vial and introducing the diluent so that it runs slowly down the inner wall, avoiding directing the stream directly onto the lyophilized cake, since vigorous mechanical agitation can fragment the peptide chains. After adding the bacteriostatic water, the vial is left to rest and gently swirled in a circular motion until a clear solution is obtained, without shaking. The chosen reconstitution volume determines the final concentration per unit of volume, a datum the researcher must record in order to precisely calculate the aliquots for their experiments. With 2 mL a more concentrated solution is obtained and with 3 mL a more dilute one, both valid according to the experimental design. It is suggested to use sterile material, work on a clean surface and verify that the solution is free of visible particles before dividing it. All handling is framed within research (RUO) and seeks to preserve the molecular integrity of both CJC-1295 without DAC and Ipamorelin during the study.

Stability and storage

The stability of this blend depends critically on the temperature conditions before and after reconstitution. In its lyophilized form, the vial preserves its integrity over a prolonged period when stored at -20 °C, protected from light and moisture; the solid and anhydrous state minimizes the hydrolysis and oxidation reactions that degrade the peptide bonds. Once reconstituted with bacteriostatic water, the material must be kept under refrigeration at 2-8 °C and used within a period of up to 30 days, since in aqueous solution peptides are more susceptible to progressive degradation. For long-duration experiments, the usual practice consists of preparing aliquots and avoiding repeated freeze-thaw cycles, which introduce physicochemical stress and reduce potency. It is advisable to protect the solutions from light exposure and from prolonged room temperatures. Both CJC-1295 without DAC and Ipamorelin are sensitive to heat and excessive agitation, so transport and handling must be careful. Documenting the reconstitution date and the storage conditions makes it possible to correlate stability with the experimental results and guarantees the traceability required in all research work (RUO).

Safety profile

In the research context (RUO), the profile of this blend is described from the established pharmacological properties of its components, without extrapolating to clinical use. A distinctive trait is the high selectivity of Ipamorelin for the ghrelin receptor GHSR-1a, which in the preclinical literature is associated with GH release without significantly elevating cortisol or prolactin levels, unlike older secretagogues. CJC-1295 without DAC, by acting on the specific GHRH receptor and presenting a limited half-life of approximately 30 minutes, favors defined pulses that approach the physiological pattern and avoid sustained stimulation of the axis. This combination of selectivity and controlled kinetics is the basis of the experimental interest in the blend over less specific stimuli. Like all research material, it must be handled in laboratory settings with adequate protective equipment, aseptic techniques, and trained personnel. The product is distributed strictly for research and is not intended for diagnosis or for applications outside the laboratory. The information presented here is for scientific and descriptive purposes, and any safety characterization corresponds to experimental models and to the documented pharmacology of the peptides, not to clinical contexts.

Comparative context

Understanding the place of this blend requires contrasting it with related alternatives within GH secretagogue research. Compared with CJC-1295 with DAC, the DAC-free version of this blend offers a much shorter half-life (close to 30 minutes versus several days), which produces sharp, well-defined pulses instead of a sustained elevation of GH; this makes it preferable in studies seeking to reproduce physiological pulsatile secretion. Compared with other GHRPs such as GHRP-6 and GHRP-2, the advantage of incorporating Ipamorelin lies in its selectivity: while GHRP-6 and GHRP-2 tend to raise cortisol and prolactin, and GHRP-6 even markedly stimulates appetite, Ipamorelin activates GH secretion more cleanly, without that effect on the stress axes. Compared with exogenous somatropin, which introduces recombinant GH directly, this blend acts indirectly by stimulating the somatotrophs to release their own GH, preserving endogenous feedback mechanisms. For this reason, in the research-peptide catalog in Mexico the CJC-1295 Ipamorelin combination is studied as a GH blend that balances synergy, selectivity, and physiological kinetics, offering a differentiated experimental profile.

History and development

The development of this combination is supported by two lineages of peptide research that converged in the neuroendocrinology of growth hormone. The study of GHRH and its active fragments led to the identification of the first 29 amino acids (GRF 1-29) as the minimal portion capable of stimulating the GHRHR; subsequently, the introduction of substitutions such as D-Ala2, Gln8, Ala15, and Leu27 gave rise to Modified GRF 1-29, known commercially as CJC-1295 without DAC, with the aim of resisting degradation by DPP-IV without resorting to the albumin-binding complex (DAC) that prolongs the half-life. In parallel, research on GH-releasing peptides (GHRP) evolved from molecules such as GHRP-6 and GHRP-2 toward Ipamorelin, designed specifically to maximize selectivity for the ghrelin receptor and minimize effects on cortisol and prolactin. The observation that GHRH analogs and GHRPs act synergistically on somatotropes motivated the practice of combining them, and from there arose the interest in presenting both peptides in a single blend for research. This historical convergence explains why the CJC-1295 Ipamorelin combination has been consolidated as an object of study in the experimental characterization of the somatotropic axis.

FAQ

Customer reviews

Average rating: 4.9 out of 5, based on 15 customer ratings.

Scientific references (8)

Peer-reviewed literature on CJC-1295 (No DAC) + Ipamorelin, with its PubMed identifier when available:

• Growth hormone (GH)-releasing peptide stimulates GH release in normal men and acts synergistically with GH-releasing hormone (Bowers, et al. · Journal of Clinical Endocrinology & Metabolism · 1990) PMID 2108187.
• Ipamorelin, the first selective growth hormone secretagogue. (Raun K, et al. · Eur J Endocrinol · 1998) PMID 9849822.
• Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers. (Gobburu JV, et al. · Pharm Res · 1999) PMID 10496658.
• Prospective, randomized, controlled, proof-of-concept study of the Ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients. (Beck DE, et al. · Int J Colorectal Dis · 2014) PMID 25331030.
• Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog. (Jetté L, et al. · Endocrinology · 2005) PMID 15817669.
• Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. (Teichman SL, et al. · J Clin Endocrinol Metab · 2006) PMID 16352683.
• Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. (Ionescu M, et al. · J Clin Endocrinol Metab · 2006) PMID 17018654.
• Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance. (Mendias CL, et al. · Sports Med · 2026) PMID 41966639.

Otras presentaciones de CJC-1295 (Sin DAC) + Ipamorelina

• CJC-1295 (DAC)
• CJC-1295 (Without DAC)

Other related research peptides

• GHRP-2
• GHRP-6
• HCG (Chorionic Gonadotropin)
• Hexarelin
• HGH (Somatropin)
• HMG (Menotropin)
• IGF-1 LR3
• Ipamorelin
• Kisspeptin
• MGF